Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Nov 5 (Reuters) - Pfizer (PFE.N) plans to sweeten its bid for Metsera (MTSR.O), a person familiar with the matter told ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.